Vol 4, No 6S (2010)

Table of Contents

Editorial

Nilotinib: selective inhibitor as second-line therapy
Massimo Breccia
PDF
3-5

Case report

Successful nilotinib therapy in a CML affected patient with A380T, P407S and V468A mutations, and a previous suboptimal cytogenetic response to imatinib
Fabio Stagno, Alessandra Cupri, Stefania Stella, Michele Massimino, Silvia Rita Vitale, Paolo Vigneri
PDF
7-11
Chronic myeloid leukemia: successful therapy with nilotinib in a young patient with high Sokal risk and in sub-optimal response with imatinib
Fausto Palmieri
PDF
13-16
Nilotinib after imatinib failure
Luca Pezzullo
PDF
17-21
Efficacy of nilotinib therapy in patient with CML diagnosed in pre-TKI era and resistant to imatinib
Ivana Pierri, Micaela Bergamaschi, Antonia Cagnetta, Anna Ghiso, Marco Gobbi
PDF
23-26